arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 5/2011 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    SPOT ON

    The 800 million dollar myth … What does drug development actually cost?

    NEW ON THE MARKET

    Oral immunosuppressant fingolimod (GILENYA) for multiple sclerosis

    THERAPY FROM A CRITICAL VIEWPOINT

    Bevacizumab: alternative to ranibizumab for macular degeneration

    a-t READER'S QUESTIONS AND COMMENTS

    Costs of coagulation self-testing

    IN BRIEF

    ´Gastroenterology´ retracts study on pancreatitis with exenatide (BYETTA) and sitagliptin (JANUVIA, XELEVIA)

    CURRENT ADR NETWORK REPORT

    Agranulocytosis and anaphylaxis due to metamizol (NOVALGIN, generics)
    free

    SIDE EFFECTS

    Update: progressive leukencephalopathy with natalizumab (TYSABRI)

    New data on thromboembolism due to oral contraceptives containing drospirenone

    e a-t IN THE INTERNET

    Great Britain: no routine pneumococcal vaccination of elderly

    Confirmed: Swine flu vaccine (PANDEMRIX) and narcolepsy

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles